Pomalidomide
Showing 26 - 50 of 253
Diffuse Large B Cell Lymphoma Trial in Suzhou (Rituximab, Orelabrutinib, Pomalidomide)
Recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab
- +4 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Apr 10, 2023
Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)
Recruiting
- Primary Central Nervous System Lymphoma
- Orelabrutinib
- +3 more
-
Beijing, Beijing, China
- +2 more
May 19, 2022
Multiple Myeloma Trial in Torino (Pomalidomide, Cyclophosphamide, Prednisone)
Active, not recruiting
- Multiple Myeloma
- Pomalidomide, Cyclophosphamide, Prednisone
-
Torino, ItalyAOU Città della Salute e della Scienza di Torino - SC Ematologia
Mar 24, 2022
Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)
Not yet recruiting
- Multiple Myeloma
- +8 more
- Belantamab Mafodotin-Blmf
- +3 more
- (no location specified)
Oct 13, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Relapsed/Refractory Multiple Myeloma Trial in La Jolla (Ixazomib, Pomalidomide, Dexamethasone)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Ixazomib
- +3 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Mar 7, 2022
Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)
Not yet recruiting
- Relapsed Refractory Multiple Myeloma
- REGN5458
- +3 more
- (no location specified)
Feb 6, 2023
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,
Active, not recruiting
- Refractory Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- ixazomib citrate
- +2 more
-
Scottsdale, Arizona
- +4 more
Mar 28, 2022
Plasma Cell Myeloma Trial in Atlanta (Belantamab Mafodotin, Dexamethasone, Pomalidomide)
Recruiting
- Plasma Cell Myeloma
- Belantamab Mafodotin
- +2 more
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Jul 21, 2022
Multiple Myeloma Trial in Milwaukee (Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide)
Recruiting
- Multiple Myeloma
- Isatuximab (for run-in portion)
- +4 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Feb 18, 2022
Relapsed/Refractory Multiple Myeloma With Pomalidomide in
Recruiting
- Multiple Myeloma
- Pomalidomide
- +2 more
-
Feldkirch, Austria
- +12 more
May 16, 2022
Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)
Recruiting
- Multiple Myeloma in Relapse
- Selinexor
- +4 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Jan 31, 2023
Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Israel (ixazomib-pomalidomide-dexamethasone)
Recruiting
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
-
Afula, Israel
- +7 more
Jul 10, 2022
Multiple Myeloma Trial (pomalidomide, Bortezomib, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- pomalidomide
- +2 more
- (no location specified)
Jun 20, 2022
Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma Trial in Rochester, Nashville (Dexamethasone, Ixazomib Citrate,
Active, not recruiting
- Plasma Cell Leukemia
- +2 more
- Dexamethasone
- +3 more
-
Rochester, Minnesota
- +1 more
May 19, 2022
Multiple Myeloma Trial in Shanghai (Selinexor, Thalidomide, Lenalidomide)
Recruiting
- Multiple Myeloma
- Selinexor
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Mar 3, 2022
CNS Tumors, Medulloblastoma Trial in Worldwide (Pomalidomide)
Active, not recruiting
- Central Nervous System Neoplasms
- Medulloblastoma
- Pomalidomide
-
Stanford, California
- +24 more
Sep 28, 2022
Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)
Recruiting
- Multiple Myeloma
- Selinexor 60 MG
- +6 more
-
Washington, District of Columbia
- +1 more
Feb 3, 2022
Multiple Myeloma Trial in Duarte, Boston, Portland (SL-401/ Pomalidomide/ Dexamethasone)
Terminated
- Multiple Myeloma
- SL-401/ Pomalidomide/ Dexamethasone
-
Duarte, California
- +2 more
Jan 13, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 3, 2022